U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07209644) titled 'Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis' on Sept. 29.
Brief Summary: This study investigates the relationship between serum catestatin levels and systemic sclerosis (SSc), with a focus on cardiovascular involvement and microvascular alterations, to determine catestatin's potential as a biomarker of disease activity and severity.
Study Start Date: Nov. 01, 2026
Study Type: OBSERVATIONAL
Condition:
Systemic Sclerosis
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Assiut University
Information provided by (Responsible Party): Esraa awwad abdoh radwan, Assiut Universi...